Which condition causes complete unilateral sensorineural hearing loss that would benefit from oral corticosteroid therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sudden Sensorineural Hearing Loss (SSNHL)

The condition that causes complete unilateral hearing loss benefiting from oral steroids is idiopathic sudden sensorineural hearing loss (SSNHL), defined as acute onset (within 72 hours) of unilateral hearing loss of 30 dB or greater across at least three contiguous frequencies, confirmed by audiometry. 1

Clinical Presentation

SSNHL typically presents with:

  • Abrupt unilateral hearing loss (often noticed upon waking)
  • Tinnitus (loud ringing)
  • Vertigo or balance problems
  • Aural fullness or pressure
  • May be accompanied by nausea 1

The key distinguishing feature is the sudden onset - patients can often pinpoint the exact moment or day it occurred. This is an otologic emergency requiring urgent evaluation, ideally within 14 days of onset 1.

Diagnostic Confirmation

Audiometry is mandatory - you cannot diagnose SSNHL without formal hearing testing showing sensorineural pattern loss. Pure tone audiometry will demonstrate:

  • Unilateral sensorineural hearing loss (air and bone conduction both affected)
  • Loss of ≥30 dB across three contiguous frequencies
  • In complete/profound cases: thresholds >90 dB with unobtainable speech reception threshold 2

Routine labs and imaging are not required initially, but MRI of internal auditory canals should be considered to exclude vestibular schwannoma (present in rare cases) 1.

Treatment Algorithm with Oral Steroids

First-Line: Systemic Corticosteroids

Initiate immediately, ideally within 14 days of onset (benefit reported up to 6 weeks but outcomes decline with delay) 1, 3:

Dosing options 1:

  • Prednisone 1 mg/kg/day (usual max 60 mg/day) for 7-14 days, then taper over similar period
  • Methylprednisolone 48 mg/day
  • Dexamethasone 10 mg/day

Do not divide doses - give as single daily dose 1.

The evidence for systemic steroids is equivocal from randomized trials, but they remain standard of care based on guideline consensus and observational data showing benefit, particularly in severe cases 1, 4. A 2003 retrospective analysis demonstrated significant improvement (p<0.01) in severe-to-profound cases treated with steroids versus untreated patients 4.

Alternative: Intratympanic Steroids as Primary Therapy

For patients with contraindications to systemic steroids (insulin-dependent diabetes, poorly controlled hypertension, glaucoma, tuberculosis, peptic ulcer disease, psychiatric reactions to steroids), intratympanic (IT) steroid injection is non-inferior 1, 5:

  • A 2011 randomized trial of 250 patients showed IT methylprednisolone was non-inferior to oral prednisone (PTA improvement 28.7 dB vs 30.7 dB, difference only 2.0 dB) 5
  • IT dexamethasone 24 mg/mL or methylprednisolone 40 mg/mL
  • 4 injections over 2 weeks
  • Patient keeps head tilted (affected ear up) for 15-30 minutes after injection 1

Salvage Therapy for Incomplete Recovery

If hearing does not recover after initial treatment, offer intratympanic steroids as salvage therapy - this has the strongest evidence with Grade A recommendation 6:

  • Salvage IT provides significant benefit (OR: 6.04,95% CI: 3.26-11.2, NNT≈3) 6
  • Initiate after 2 weeks if initial therapy fails 1
  • Same dosing protocol as primary IT therapy

Combined Initial Therapy Consideration

For severe to profound hearing loss specifically, recent evidence suggests combined systemic plus intratympanic steroids as initial therapy may be superior 7:

  • Greater PTA improvement (31.0±10.0 dB vs 45.0±9.8 dB) and higher complete recovery rates (46.5% vs 29.4%, p=0.005) 7
  • Improved speech discrimination (72.3% vs 57.4%, p=0.042) 7
  • However, this represents newer evidence with moderate risk of bias, and the 2019 AAO-HNS guideline does not yet strongly endorse this as routine initial approach 1

Prognosis Factors

Better outcomes occur with 1, 3:

  • Earlier treatment initiation (within first 2 weeks)
  • Milder degree of initial hearing loss
  • Recovery of at least half the hearing within first 2 weeks predicts better final outcome
  • Absence of vertigo at onset

Poorer prognosis 1:

  • Presence of dizziness/vertigo at onset
  • Profound initial hearing loss
  • Delayed presentation beyond 2 weeks
  • Minimal change within first 2 weeks

Approximately one-third to two-thirds of patients recover some hearing spontaneously within 2 weeks, which complicates interpretation of treatment efficacy 1.

Monitoring

  • Audiogram at completion of treatment (2 months) and delayed intervals 1
  • Follow-up audiometry within 6 months of diagnosis 1
  • For IT injections: interval audiograms between injections may guide early termination if hearing resolves 1
  • Inspect tympanic membrane for healing after IT therapy 1

Critical Pitfalls

Shared decision-making is essential given equivocal evidence for systemic steroids and potential adverse effects 1. However, adverse events are rare and manageable with the short 10-14 day course recommended (most serious effects occur with chronic use) 1.

Common steroid side effects include hyperglycemia, weight gain, insomnia, hypertension, mood changes, and gastric irritation 1. Monitor glucose and blood pressure in susceptible patients 1.

Do not delay treatment waiting for spontaneous recovery - the window for maximal benefit is narrow, and early intervention correlates with better outcomes 3.

References

Guideline

clinical practice guideline: sudden hearing loss (update).

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2019

Research

Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.